You will not find a more unique, expansive opportunity for your CRISPR research. Anywhere.
MilliporeSigma has announced a new licensing collaboration with the Broad Institute that can simplify your path to licensing CRISPR technology, while making it more widely available to the global research and discovery community at large.
When you partner with MilliporeSigma, you will not only have access to MilliporeSigma’s 18 CRISPR patents (including IP for CRISPR integration technology), but you will also have access to the Broad Institute licenses to Broad-managed IP for internal research use and for commercial research tools and kits.
Here’s what you will receive.
As always, ethics is a priority.
MilliporeSigma supports research with genome editing under careful consideration of ethical and legal standards. Its parent company, Merck KGaA, Darmstadt, Germany, has established an independent, external Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing, and has defined a clear operational position taking into account scientific and societal issues to inform promising therapeutic approaches for use in research and applications.
Ready to talk about how MilliporeSigma can expand your CRISPR research with our exclusive CRISPR licensing portfolio?
Contact us here:
Fields indicated by an * are required.
For further inquiries, contact:
Head of Business Development & IP Strategies for Gene Editing and Novel Modalities
MilliporeSigma | 2909 Laclede Ave | 63103 | St Louis, MO | USA
Phone: +1 314 286-7923 | Mobile: +1 314 704-3706
E-mail: email@example.com | www.milliporesigma.com